Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review

Jong, Joyce M. van Dodewaard-de; Oprea-Lager, Daniela E.; Hooft, Lotty; Klerk, John M. H. de; Bloemendal, Haiko J.; Verheul, Henk M.W.; Hoekstra, Otto S.; Eertwegh, Alfons J.M. van den

doi:10.1016/j.eururo.2015.09.005

Cited by 57 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pattern of bone involvement can have important implications for prognosis (52,54) and management (53). For instance, unifocal involvement may be targetable with curative intent by external-beam radiation therapy, and diffuse marrow involvement indicates elevated risk for hematotoxicity after radionuclide therapy (55)(56)(57).…”

Section: Extrapelvic Nodes and Distant Metastases (M)mentioning

confidence: 99%

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

et al. 2017

View full text Add to dashboard Cite

See an invited perspective on this article on page 466. Prostate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.

show abstract

Section: Extrapelvic Nodes and Distant Metastases (M)mentioning

confidence: 99%

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It is well known that bone-targeting drugs significantly reduce the incidence of SREs (17). This effect has also been demonstrated for another novel systemic treatment options, including radionuclide treatment with the α-emitter radium-223 (18)(19)(20). In addition, survival improved significantly with radium-223 treatment compared with placebo (18).…”

Section: Discussionmentioning

confidence: 68%

Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer

Nieder¹,

Haukland²,

Mannsåker³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. More effective drugs may reduce the requirement for palliative external beam radiotherapy for bony target volumes; however, living with metastases for prolonged periods of time may result in more frequent episodes of bone pain or serious skeletal-related events. The purpose of the present study was to evaluate how recent advances in systemic therapy impact radiotherapy utilization. A retrospective analysis of a comprehensive regional database was performed. All oncology care in this region was provided by only one center, assuring complete data. Patients that had succumbed between June 1, 2004 and June 1, 2015 were included. For all 236 patients, the median age at diagnosis of bone metastases was 75 years and median overall survival was 20 months. More intense systemic therapy was associated with a significantly longer survival time. Only 69 patients (29%) did not receive palliative radiotherapy for bony target volumes, whilst 1 course was given to 101 patients (43%), 2 courses to 34 patients (14%) and >2 courses to 32 patients (14%). Radiotherapy was used more frequently in younger patients, those with spinal cord compressions or pathological fractures, and those treated with intense and long-standing systemic therapy. Radiotherapy utilization increased with survival time. For 100 poor-prognosis patients that succumbed within 12 months, 57 courses of palliative radiotherapy were administered, whilst 100 patients that survived for 12-24 months were administered 114 courses (24-36 months, 148 courses). In conclusion, the use of palliative radiotherapy did not decrease when more effective systemic therapy was administered. However, provided that only 5% of patients received radionuclide treatment, additional studies in other populations are required.

show abstract

“…While the only bone-targeted radiopharmaceutical to show improved survival in prostate cancer was Ra-223, others have demonstrated to improve pain control [ 99 ]. These include the beta emitters’ rhenium-186, rhenium-188, samarium-153 and strontium-89.…”

Section: Validated Targetsmentioning

confidence: 99%

Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?

Casimiro

Ferreira

Mansinho

et al. 2016

IJMS

View full text Add to dashboard Cite

Bone metastases ultimately result from a complex interaction between cancer cells and bone microenvironment. However, prior to the colonization of the bone, cancer cells must succeed through a series of steps that will allow them to detach from the primary tumor, enter into circulation, recognize and adhere to specific endothelium, and overcome dormancy. We now know that as important as the metastatic cascade, tumor cells prime the secondary organ microenvironment prior to their arrival, reflecting the existence of specific metastasis-initiating cells in the primary tumor and circulating osteotropic factors. The deep comprehension of the molecular mechanisms of bone metastases may allow the future development of specific anti-tumoral therapies, but so far the approved and effective therapies for bone metastatic disease are mostly based in bone-targeted agents, like bisphosphonates, denosumab and, for prostate cancer, radium-223. Bisphosphonates and denosumab have proven to be effective in blocking bone resorption and decreasing morbidity; furthermore, in the adjuvant setting, these agents can decrease bone relapse after breast cancer surgery in postmenopausal women. In this review, we will present and discuss some examples of applied knowledge from the bench to the bed side in the field of bone metastasis.

show abstract

Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review

Cited by 57 publications

References 38 publications

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer

Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?

Contact Info

Product

Resources

About